- Home
- KPTI vs BRIA Comparison
KPTI vs BRIA Comparison
Compare KPTI & BRIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- BRIA
- Stock Information
- Founded
- KPTI 2008
- BRIA 2011
- Country
- KPTI United States
- BRIA Singapore
- Employees
- KPTI N/A
- BRIA N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- BRIA
- Sector
- KPTI Health Care
- BRIA
- Exchange
- KPTI Nasdaq
- BRIA NYSE
- Market Cap
- KPTI 44.5M
- BRIA 62.0M
- IPO Year
- KPTI 2013
- BRIA 2024
- Fundamental
- Price
- KPTI $4.39
- BRIA $2.48
- Analyst Decision
- KPTI Buy
- BRIA
- Analyst Count
- KPTI 6
- BRIA 0
- Target Price
- KPTI $48.50
- BRIA N/A
- AVG Volume (30 Days)
- KPTI 53.3K
- BRIA 3.6K
- Earning Date
- KPTI 08-05-2025
- BRIA 08-15-2025
- Dividend Yield
- KPTI N/A
- BRIA N/A
- EPS Growth
- KPTI N/A
- BRIA N/A
- EPS
- KPTI N/A
- BRIA 92.24
- Revenue
- KPTI $142,126,000.00
- BRIA $59,695,825.00
- Revenue This Year
- KPTI $2.09
- BRIA N/A
- Revenue Next Year
- KPTI $12.90
- BRIA N/A
- P/E Ratio
- KPTI N/A
- BRIA $0.03
- Revenue Growth
- KPTI 1.19
- BRIA 8.03
- 52 Week Low
- KPTI $3.51
- BRIA $1.78
- 52 Week High
- KPTI $16.95
- BRIA $4.38
- Technical
- Relative Strength Index (RSI)
- KPTI 45.76
- BRIA N/A
- Support Level
- KPTI $4.12
- BRIA N/A
- Resistance Level
- KPTI $4.85
- BRIA N/A
- Average True Range (ATR)
- KPTI 0.31
- BRIA 0.00
- MACD
- KPTI 0.04
- BRIA 0.00
- Stochastic Oscillator
- KPTI 36.99
- BRIA 0.00
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.